Fig. 2. LINC01468 silencing suppresses the chemoresistance of HCC cells and inhibits HCC tumorigenesis by lipid metabolism.
A CCK8 assays in SNU-449 and HCC-LM3 cells transfected with or without shLINC01468. B Representative images (left panel) and number (right panel) of migratory or invasive cells transfected with the scrambled control or shLINC01468. C Representative images (left panel), weight (middle panel), and growth (right panel) of xenografts derived from HCC cells stably transfected with the scrambled control or shLINC01468. D The viability of SNU-449 cells transfected with shLINC01468 or scrambled control in the presence of different concentrations of lenvatinib (LVB) treatment was examined by the CCK8 assay. E A representative image of colony formation of SNU-449 cells transfected with shLINC01468 or scrambled control after treatment with 5 μM LVB. F, G Representative tumor images (F) and tumor growth curves (G) of xenografts derived from SNU-449 cells stably transfected with shLINC01468 or scrambled control in the presence or absence of intraperitoneal LVB injections. The right flanks of all the mice were subcutaneously injected with 5 × 106 cells. The tumors were collected after 4 weeks. H Viability of Huh7 cells transfected with LINC01468 or Ctrl in the presence of different concentrations of sorafenib was examined by the CCK8 assay. I A representative image of colony formation of Huh7 cells transfected with LINC01468 or Ctrl after treatment with 20 μg/mL of sorafenib. J, K Representative tumor images (J) and tumor growth curves (K) of xenografts derived from Huh7 cells stably transfected with LINC01468 or control in the presence or absence of intraperitoneal injections of 20 μg/mL sorafenib. The right flanks of the mice were subcutaneously injected with 5 × 106 cells. The tumors were collected after 4 weeks. The data represent the means ± S. D (*P < 0.05; **P < 0.01).